Details van artikel 188 van 200 gevonden artikelen
167TiP AdvanTIG-301: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) + tislelizumab (TIS) + concurrent chemoradiotherapy (cCRT) followed by OCI + TIS or TIS + cCRT followed by TIS vs cCRT followed by durvalumab (DUR) in previously untreated, locally advanced, unresectable NSCLC
Titel:
167TiP AdvanTIG-301: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) + tislelizumab (TIS) + concurrent chemoradiotherapy (cCRT) followed by OCI + TIS or TIS + cCRT followed by TIS vs cCRT followed by durvalumab (DUR) in previously untreated, locally advanced, unresectable NSCLC
Auteur:
Xing, L. Yu, J. Peters, S. Besse, B. Spira, A. Wang, J. Yang, Y. Wang, H.
Verschenen in:
Annals of oncology
Paginering:
Jaargang 32 () nr. S7 pagina's S1455
Jaar:
2021
Inhoud:
Uitgever:
European Society for Medical Oncology
Bronbestand:
Elektronische Wetenschappelijke Tijdschriften
Details van artikel 188 van 200 gevonden artikelen